Dianthus Therapeutics (DNTH) News
NASDAQ: DNTHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
84.55-0.28 (-0.33%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DNTH news summary
We found 10 recent headlines mentioning Dianthus Therapeutics (DNTH): 0 in the past week and 8 in the past 30 days, most often from Nasdaq, GlobeNewswire, Seeking Alpha. For price context, DNTH is down 0.33% at $84.55. The most recent story, "Dianthus Therapeutics, Inc. Reports Q3 2026 Financial Results and Highlights Clinical Progress", was published by Nasdaq on Nov 4, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Dianthus Therapeutics headlines
- Dianthus Therapeutics, Inc. Reports Q3 2026 Financial Results and Highlights Clinical ProgressDianthus Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline. The company reported approximately $1.2…Nasdaq
- Dianthus Therapeutics GAAP EPS of -$0.81 beats by $0.18Seeking Alpha
- Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial ResultsAdvancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic…GlobeNewswire
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…GlobeNewswire
- Dianthus Therapeutics to Participate in Five Investor Conferences During NovemberNEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…GlobeNewswire
- Regeneron (REGN) Q3 Earnings and Revenues Beat EstimatesRegeneron (REGN) delivered earnings and revenue surprises of +24.81% and +12.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqREGN, DNTH
- Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings GrowthHalozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.NasdaqHALO, DNTH
- Why is Dianthus Therapeutics stock gaining today?Investing.com
- Dianthus Therapeutics Enters Oversold Territory (DNTH)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a…Nasdaq
- Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharmaNEW YORK and WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to…GlobeNewswire